The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder

Journal of Affective Disorders

Volumn 127, Issue 1-3, 2010, Pages 343-351

  Gudayol Ferré, Esteve ^a,b,c   Herrera Guzmán, Ixchel ^a,b,c   Camarena, Beatriz ^f   Cortés Penagos, Carlos ^b   Herrera Abarca, Jorge E ^a,c   Martínez Medina, Patricia ^d   Cruz, David ^b   Hernández, Sandra ^f   Genis, Alma ^f   Carrillo Guerrero, Mariana Y ^b   Avilés Reyes, Rubén ^b   Guàrdia Olmos, Joan ^e,g  

^a CECYPE   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d El Centro Michoacano de Salud Mental Morelia   (Mexico)

^e UNIVERSITY OF BARCELONA   (Spain)

^f INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^g Institut de Recerca Cervell Cognició i Conducta IR3C   (Spain)

Author keywords

5HTTLPR; Antidepressant response; COMT; Major depressive disorder; Neuropsychological assessment; Polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; FLUOXETINE; SEROTONIN TRANSPORTER;

ADULT; ANXIETY DISORDER; ARTICLE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; ATTENTION; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PERSONALITY INVENTORY; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 78149361693     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2010.06.002     Document Type: Article

References (61)

1. E. Airaksinen, M.L. Larsson, I. Lundberg, and Y. Forsell Cognitive functions in depressive disorders: evidence from a population based study Psychol. Med. 34 2004 83 91
2. G.S. Alexopoulos, D.N. Kioses, N. Heo, C.F. Murphy, B. Shanmugham, and F. Gunning-Dixon Executive dysfunction and the course of geriatric depression Biol. Psychiatry 58 2005 204 210
3. I.M. Anderson SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability Depress. Anxiety 7 1998 S1 S11
4. B. Arias, R. Catalán, C. Gasto, B. Gutiérrez, and L. Fañanás 5-HTTLPR polymorphism of the serotonin transporter gene predicts nonremission in major depression patients treated with citalopram in a 12-week follow-up study J. Clin. Psychopharmacol. 23 2003 563 567
5. B. Arias, A. Serretti, C. Lorenzi, C. Gastó, R. Catalán, and L. Fañanás Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin J. Affect. Disord. 90 2006 2 3
6. M.P. Austin, P.M. Mitchell, and G.M. Goodwin Cognitive deficits in depression Br. J. Psychiatry 178 2001 200 206
7. R.M. Bagby, A.G. Ryderm, and C. Cristi Psychosocial and clinical predictors of response to pharmacotherapy for depression J. Psychiatry Neurosci. 27 2002 250 257
8. F. Benedetti, C. Colombo, A. Pirovano, E. Marino, and E. Smeraldi The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting Psychopharmacology 203 2009 155 160
9. W. Berrettini Psychiatric pharmacogenetics: a developing science Neuropsychopharmacology 26 2002 128 129
10. R. Chamberlain, and B. Sahakian Cognition in mania and depression. Psychological models and clinical implications Curr. Psychiatry Rep. 6 2004 451 458
11. J.R. Davidson, P. Meoni, V. Haudiquet, M. Cantillon, and D. Hackett Achieving remission with venlafaxine and fluoxetine in major depression. Its relationship to anxiety symptoms Depress. Anxiety 16 2002 4 13
12. A.Y. Deutsch, and R.H. Roth Neurotransmitters F.J. Zigmond, F.E. Bloom, S.C. Landis, J.L. Roberts, L.R. Squire, Fundamental neuroscience 2003 Academic Press San Diego 193 234
13. J.J. Dunkin, A.F. Leuchter, I.A. Cook, J.E. Kasl-Godley, M. Abrams, and S. Rosenberg-Thompson Executive dysfunction predicts nonresponse to fluoxetine in major depression J. Affect. Disord. 60 2000 13 23
14. M.F. Egan, T.E. Goldberg, B.S. Kolachana, J.H. Callicott, C.M. Mazzanti, R.E. Straub, D. Goldman, and D.R. Weintberger Effect of COMT val198/158met genotype on frontal lobe function and risk of schizophrenia Proc. Natl Acad. Sci. U. S. A. 98 2001 6917 6922
15. J. Egeland, B.O. Rund, K. Sundet, N.I. Landro, A. Asbjornsen, and A. Lund Attention profile in schizophrenia compared with depression: differential effects of processing speed, selective attention and vigilance Acta Psychiatr. Scand. 108 2003 276 284
16. M. Fava, A.J. Rush, and J.E. Alpert Difference in treatment outcome in outpatients with anxious depression versus non-anxious depression. A STAR*D report Am. J. Psychiatry 165 2008 342 351
17. S.J. Fredman, M. Fava, A.S. Kienke, C.N. White, A.A. Nieremberg, and F.J. Rosenbaum Partial response, nonresponse and relapse with selective serotonin reuptake inhibitors in major depression: a survey of "next step" practices J. Clin. Psychiatry 28 2000 143 148
18. G. Gartlehner, R.A. Hansen, P. Thieda, A.M. DeVeaugh-Geiss, B.N. Gaynes, E.E. Krebs, L.J. Lux, L.C. Morgan, J.A. Shumate, L.G. Monroe, and K.N. Lohr Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Comparative Effectiveness Review No. 7. (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) Rockville, MD: Agency for Healthcare Research and Quality 2007 Available at: www.effectivehealthcare.ahrq. gov/reports/final.cfm
19. M. Gorlyn, J.G. Keilp, M.F. Grunebaum, B.P. Taylor, M.A. Oquendo, G.E. Bruder, J.W. Stewart, G. Zalsman, and J.J. Mann Neuropsychological characteristics as predictors of SSRI treatment response in depressed patients J. Neural. Transm. 115 2008 1213 1219
20. T.C. Gualtieri, L.G. Johnson, and K.B. Benedict Neurocognition in depression: patients on and off medication versus healthy comparison subjects J. Neuropsychiatry Clin. Neurosci. 18 2006 217 225
21. M. Hamilton Development of a rating scale for primary depressive illness Br. J. Soc. Clin. Psychol. 4 1967 278 296
22. A. Heils, A. Teufel, S. Petri, G. Stöberg, P. Riederer, D. Bengel, and K.P. Lesch Allelic variation of human serotonin transporter gene expression J. Neurochem. 66 1996 2621 2624
23. I. Herrera-Guzmán, E. Gudayol-Ferré, J. Lira-Mandujano, J. Herrera-Abarca, D. Herrera-Guzmán, K. Montoya-Pérez, and J. Guàrdia-Olmos Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder Psychiatry Res. 160 2008 72 82
24. I. Herrera-Guzmán, E. Gudayol-Ferré, J.E. Herrera-Abarca, D. Herrera-Guzmán, P. Montelongo-Pedraza, F. Padros Blázquez, M. Peró-Cebollero, and J. Guárdia-Olmos Major Depresive disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery J. Affect. Disord. 123 2010 341 350
25. D.W. Hosmer, and S. Lesmeshow Applied Logistic Regression 1989 Wiley & Sons Nueva York
26. X. Hu, G. Oroszi, J. Chum, T.L. Smith, D. Goldman, and M.A. Schucki An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk Alcohol. Clin. Exp. Res. 29 2005 3 16
27. X.Z. Hu, A.J. Rush, D. Charney, A.F. Wilson, A.J. Sorant, G.J. Papanicolaou, M. Fava, M.H. Trivedi, S.R. Wisniewski, G. Laje, S. Paddock, F.J. McMahon, H. Manji, and R.H. Lipsky Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression Arch. Gen. Psychiatry 64 2007 783 792
28. K. Ito, K. Yoshida, K. Sato, H. Takahashi, M. Kamata, H. Higuchi, T. Shimizu, K. Itoh, K. Inoue, T. Tezuka, T. Suzuki, T. Ohkubo, K. Sugawara, and K. Otani A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine Psychiatry Res. 111 2002 235 239
29. P.R. Joyce, and E.S. Paykel Predictors of drug response in depression Arch. Gen. Psychiatry 46 1989 89 99
30. L.L. Judd, H.S. Akiskal, P.J. Zeller, M. Paulus, A.C. Leon, J.D. Maser, J. Endicott, W. Coryell, J.L. Kunovac, T.I. Mueller, J.P. Rice, and M.B. Keller Psychosocial disability during the long-term course of unipolar major depressive disorder Arch. Gen. Psychiatry 57 2000 375 380
31. O. Kampf-Sherf, Z. Zlotogorski, A. Gilboa, L. Speedie, J. Lereya, P. Rosca, and Y. Shavit Neuropsychological functioning and responsiveness to selective serotonin reuptake inhibitors antidepressants J. Affect. Disord. 82 2004 453 459
32. M. Kato, and A. Serretti Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder Mol. Psychiatry 15 2010 473 500
33. A.H. Kemp, E. Gordon, J. Rush, M. Leanne, and M. Williams Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging and genetic measures CNS Spectr. 13 2008 1066 1086
34. D.K. Kim, S.W. Lim, S. Lee, S.E. Sohn, S. Kim, C.G. Hahn, and B.J. Carroll Serotonin transporter gene polymorphism and antidepressant response NeuroReport 11 2000 215 219
35. J.B. Kraft, E.J. Peters, S.L. Slager, G.D. Jenkins, M.S. Reinalda, P.J. McGrath, and S.P. Hamilton Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample Biol. Psychiatry 61 2007 734 742
36. K.P. Lesch, D. Bengel, A. Helis, S.Z. Sabol, B.D. Greenberg, S. Petri, J. Benjamin, Cr. Muller, D.H. Hamer, and D.L. Murphy Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 274 1996 1527 1531
37. M.D. Lezak, D.B. Howiesson, and D.W. Loring Neuropsychological Assessment Fourth Edition 2004 Oxford University Press Oxford
38. G.M. MacQueen, T.M. Galway, J. Hay, L.T. Young, and R.T. Joffe Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status Psychol. Med. 32 2002 251 258
39. F.J. McMahon, S. Buervenich, D. Charney, R. Lipsky, A.J. Rush, A.F. Wilson, A.J. Sorant, G.J. Papanicolaou, G. Laje, M. Fava, M.H. Trivedi, S.R. Wisniewski, and H. Manji Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment Am. J. Hum. Genet. 78 2006 804 814
40. G.I. Papakostas, R.H. Perlis, M.J. Scalia, T.J. Petersen, and M. Fava A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder J. Clin. Psychopharmacol. 26 2006 56 60
41. E.J. Peters, S.L. Slager, P.J. McGrath, J.A. Knowles, and S.P. Hamilton Investigation of serotonin-related genes in antidepressant response Mol. Psychiatry 9 2004 879 889
42. R.J. Porter, P. Gallagher, M.J. Thompson, and A.H. Young Neurocognitive impairment in drug-free patients with major depressive disorder Br. J. Psychiatry 182 2003 214 220
43. M.A. Posternak, and M. Zimmerman Is there a delay in antidepressant effect? A metanalysis J. Clin. Psychiatry 66 2005 148 158
44. T.W. Robbins, M. James, A.M. Owen, B.J. Sahakian, L. McIness, and P. Rabitt Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers Dementia 5 1994 266 281
45. M.A. Rogers, K. Kasai, K. Matsuo, R. Fukuda, A. Iwanami, K. Nakagome, M. Fukuda, and K. Nobumasa Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence Neurosci. Res. 50 2004 1 11
46. A.J. Rush, M.H. Trivedi, S.R. Wisniewski, J.W. Stewart, A.A. Nierenberg, M.E. Thase, L. Ritz, M.M. Bigss, D. Warden, J.F. Luther, K. Shores-Wilson, G. Niederehe, and M. Fava Bupropion-SR, sertraline or venlafaxine XR alter failure of SSRI's for depression New Engl. J. Med. 354 2006 1231 1242
47. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 Clin. Psychiatry 59 Suppl 20 1998 22 33
48. E. Smeraldi, R. Zanardi, F. Benedetti, D. Di Bella, J. Pérez, and M. Catalano Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine Mol. Psychiatry 3 1998 508 511
49. D. Souery, P. Oswald, and Massai Clinical factors associated with treatment resistance in major depressive disorder. Results from a European multicenter study J. Clin. Psychiatry 68 2007 1062 1070
50. Stahl, 2002. Psicofarmacología esencial. Ed. Ariel, Madrid.
51. A. Szegedi, D. Rujescu, A. Tadic, M.J. Müller, R. Kohnen, H.H. Stassen, and N. Dahmen The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression Pharmacogenomics J. 5 2005 49 53
52. J. Taylor Rapid onset of true antidepressant action Curr. Psychiatry Rep. 9 2007 475 479
53. B.P. Taylor, G.E. Bruder, J.W. Stewart, P.J. McGrath, J. Halperin, H. Ehrichman, and F.M. Quitkin Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients Am. J. Psychiatry 163 2006 73 78
54. M.E. Thase, and A.J. Rush Treatment-resistant depression F.E. Bloom, D.J. Kupfer, Psychopharmacology: the fourth generation progress 1995 New York Raven Pres 1081 1098
55. S.J. Tsai, Y.T. Gau, C.J. Hong, Y.J. Liou, Y.W. Yu, and T.J. Chen Sexually dimorphic effect of catecol-o-methyltransferase val 158 met polymorphism on clinical response to fluoxetine in major depressive patients J. Affect. Disord. 113 2009 183 187
56. P. Weiland-Fielder, K. Erickson, T. Waldeck, D.A. Luckenbaurg, D. Pike, O. Boone, D. Charney, and A. Neumeister Evidence for continuing neuropsychological impairments in depression J. Affect. Disord. 82 2004 253 258
57. J. Westheide, M. Wagner, B. Quednow, C. Hoppe, D. Cooper-Mahkorn, B. Strater, W. Maier, and K.W. Kuhn Neuropsychological performancein partly remitted unipolar depressive patients: focus on executivefunctioning Eur. Arch. Psychiatry Clin. Neurosci. 257 2007 389 395
58. K. Yoshida, K. Ito, K. Sato, H. Takahashi, M. Kamata, and H. Higuchi Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 7-8 2002 1279 1283
59. Y.W. Yu, S.J. Tsai, T.J. Chen, C.H. Lin, and C.J. Hong Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders Mol. Psychiatry 7 2002 1115 1119
60. K.K. Zakzanis, T. Leach, and E. Kaplan On the nature and pattern of neurocognitive function in major depresive disorder Neuropsychiatry Neuropsychol. Behav. Neurol. 11 1998 111 119
61. R. Zanardi, F. Benedetti, D. Di Bella, M. Catalano, and E. Smeraldi efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene J. Clin. Psychopharmacol. 20 2000 105 107